Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson
McKesson
Harvard Business School
Baxter
Moodys

Last Updated: December 9, 2019

DrugPatentWatch Database Preview

LANOXICAPS Drug Profile

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

When do Lanoxicaps patents expire, and what generic alternatives are available?

Lanoxicaps is a drug marketed by Glaxosmithkline Llc and is included in one NDA.

The generic ingredient in LANOXICAPS is digoxin. There are ten drug master file entries for this compound. Thirty-seven suppliers are listed for this compound. Additional details are available on the digoxin profile page.

Summary for LANOXICAPS
Drug patent expirations by year for LANOXICAPS
Synonyms for LANOXICAPS
(3beta,5beta,12beta)-3-((O-2,6-Dideoxy-beta-D-ribo-hexapyranosyl-(1-4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl)oxy)-12,14-dihydroxycard-20(22)-enolide
(3beta,5beta,12beta)-3-{[2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl]oxy}-12,14-dihydroxycard-20(22)-enolide
[3H]-digoxin
[3H]digoxin
0B9662A7-264E-4ACD-94B2-9E1138C0CA5A
11000-95-6
12bet.-Hydroxydigitoxin
12beta-Hydroxydigitoxin
20830-75-5
3-[(3S,5R,8R,9S,10S,12R,13S,14S,17R)-3-[(2R,4S,5S,6R)-5-[(2S,4S,5S,6R)-5-[(2S,4S,5S,6R)-4,5-dihydroxy-6-methyloxan-2-yl]oxy-4-hydroxy-6-methyloxan-2-yl]oxy-4-hydroxy-6-methyloxan-2-yl]oxy-12,14-dihydr
36-35-1
39366-41-1
3b0w
3beta-((O-2,6-Dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl)oxy)-12beta,14-dihydroxy-5beta-card-20(22)-enolide
3beta,12beta,14-Trihydroxy-5beta,14beta-card-20(22)-enolid-3-tridigitoxosid
4-((1S,2S,5S,11S,15S,7R,10R,14R,16R)-5-{5-[5-((2S,4S,5S,6R)-4,5-dihydroxy-6-me thyl(2H-3,4,5,6-tetrahydropyran-2-yloxy))(4S,5S,2R,6R)-4-hydroxy-6-methyl(2H-3 ,4,5,6-tetrahydropyran-2-yloxy)](4S,5S,2R,
5-18-04-00381 (Beilstein Handbook Reference)
6R)-4-hydroxy-6-methyl(2H-3,4,5,6-te trahydropyran-2-yloxy)}-11,16-dihydroxy-2,15-dimethyltetracyclo[8.7.0.0<2,7>.0 <11,15>]heptadec-14-yl)-5-hydrofuran-2-one
73K4184T59
8001-36-3
8001-37-4
8001-52-3
82476-60-6
830D755
A814956
AC1MC4TN
AC1Q29PT
Acygoxin
AKOS015895113
AKOS024283494
AN-18552
AS-13281
B7684
BDBM46355
BIDD:PXR0148
BPBio1_000500
BRD-K23478508-001-03-7
BRN 0077011
BSPBio_000454
C-23516
C06956
C41H64O14
Card-20(22)-enolide, 3-((O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl)oxy)-12,14-dihydroxy-, (3beta,5beta,12beta)-
Card-20(22)-enolide, 3-((O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl)oxy)-12,14-dihydroxy-, (3beta,5beta,12beta)-
Card-20(22)-enolide, 3-((O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1.fwdarw.4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1.fwdarw.4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl)oxy)-12,14-dihydroxy-, (3beta,5beta,12beta)-
Card-20(22)-enolide, 3-[[O-2,6-dideoxy-.beta.-D-ribo-hexopyranosyl-(1-->4)-O-2,6-dideoxy-.beta.-D-ribo-hexopyranosyl-(1-->4)-2,6-dideoxy-.beta.-D-ribo-hexopyranosyl]oxy]-12,14-dihydroxy-, (3.beta.,5.beta.,12.beta.)-
Cardigox
Cardiogoxin
Cardioxin
CAS-20830-75-5
CC-26802
CCG-220437
CHEBI:4551
CHEMBL1751
Chloroformic digitalin
cid_2724385
Cogoxin
Coragoxine
Cordioxil
CS-4571
D00298
D1828
Davoxin
DB00390
Digacin
Digazolan
Digitalis glycoside
Digitek
Digoksyna
Digoksyna [Polish]
Digomal
Digon
Digonix
Digos
Digosin
Digossina
Digossina [DCIT]
Digoxigenin-tridigitoxosid
Digoxigenin-tridigitoxosid [German]
digoxin
Digoxin (JP17/USP)
Digoxin [USP:INN:BAN:JAN]
Digoxin 1.0 mg/ml in Methanol
Digoxin for peak identification, European Pharmacopoeia (EP) Reference Standard
Digoxin Nativelle
Digoxin Pediatric
Digoxin solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material
Digoxin-Sandoz
Digoxin-Zori
Digoxin, 95%
Digoxin, analytical standard
Digoxin, certified reference material, TraceCERT(R)
Digoxin, European Pharmacopoeia (EP) Reference Standard
Digoxin, Pharmaceutical Secondary Standard; Certified Reference Material
Digoxin, United States Pharmacopeia (USP) Reference Standard
Digoxina
Digoxina [INN-Spanish]
Digoxina-Sandoz
Digoxine
Digoxine Navtivelle
Digoxinum
Digoxinum [INN-Latin]
Dilanacin
Dimecip
Dixina
Dokim
DSSTox_CID_2934
DSSTox_GSID_22934
DSSTox_RID_76794
DTXSID5022934
Dynamos
EINECS 244-068-1
Epitope ID:122964
Eudigox
Fargoxin
Grexin
GTPL4725
GTPL4726
H797
Hemigoxine Nativelle
HMS1569G16
HMS2096G16
HMS2232G20
HMS3713G16
Homolle's digitalin
HSDB 214
HY-B1049
J-013666
J10027
Lanacordin
Lanacrist
Lanadicor
Lanicor
Lanikor
Lanorale
Lanoxicaps (TN)
Lanoxin
Lanoxin (TN)
LANOXIN PEDIATRIC
Lanoxin PG
Lenoxicaps
Lenoxin
Lifusin
Longdigox
LTMHDMANZUZIPE-PUGKRICDSA-N
Mapluxin
MCULE-8165628529
MFCD00003674
MLS000069819
MLS001055371
MLS001076495
MolPort-002-536-760
Natigoxin
NCGC00090797-01
NCGC00090797-02
NCGC00090797-03
NCGC00090797-04
NCGC00090797-05
NCGC00090797-06
NCGC00090797-07
NCGC00090797-09
NCGC00090797-15
NCGC00257022-01
NCGC00259227-01
Neo-Lanicor
Neodioxanin
Novodigal [inj.]
NSC 95100
OioC>>uNomicroO>>AE paragraph sign(3/4)UO
Opera_ID_1134
oxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2H-furan-5-one
Prestwick_170
Prestwick0_000437
Prestwick1_000437
Prestwick2_000437
Prestwick3_000437
Purgoxin
REGID_for_CID_2724385
Rougoxin
s4290
Saroxin
SCHEMBL20506
SK-Digoxin
SMR000059217
SMR000653537
SPBio_002393
SR-01000721866
SR-01000721866-3
SR-01000721866-4
ST069334
Stillacor
Tox21_111025
Tox21_201678
Tox21_303050
UNII-73K4184T59
Vanoxin
ZINC242548690
ZX-AFC001295

US Patents and Regulatory Information for LANOXICAPS

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaxosmithkline Llc LANOXICAPS digoxin CAPSULE;ORAL 018118-002 Jul 26, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
Glaxosmithkline Llc LANOXICAPS digoxin CAPSULE;ORAL 018118-001 Jul 26, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
Glaxosmithkline Llc LANOXICAPS digoxin CAPSULE;ORAL 018118-003 Jul 26, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
Glaxosmithkline Llc LANOXICAPS digoxin CAPSULE;ORAL 018118-004 Sep 24, 1984 DISCN No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for LANOXICAPS

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Glaxosmithkline Llc LANOXICAPS digoxin CAPSULE;ORAL 018118-002 Jul 26, 1982   Start Trial   Start Trial
Glaxosmithkline Llc LANOXICAPS digoxin CAPSULE;ORAL 018118-001 Jul 26, 1982   Start Trial   Start Trial
Glaxosmithkline Llc LANOXICAPS digoxin CAPSULE;ORAL 018118-004 Sep 24, 1984   Start Trial   Start Trial
Glaxosmithkline Llc LANOXICAPS digoxin CAPSULE;ORAL 018118-003 Jul 26, 1982   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Mallinckrodt
Johnson and Johnson
Medtronic
Express Scripts
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.